Febrile Neutropenia Market Size Forecasted To Achieve 14.47 Billion By 2029 With Steady Growth

We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.

What Is the Febrile Neutropenia Market Size and Projected Growth Rate?
The market for febrile neutropenia has seen significant expansion in the past years. The market, which was valued at $10.60 billion in 2024, is projected to climb to $11.31 billion in 2025, reflecting a compound annual growth rate (CAGR) of 6.7%. The growth witnessed in the past period is credited to factors such as the increasing occurrence of cancer, the rising uptake of chemotherapy treatments, the growth of personalized medicine, the decreasing healthcare costs, and the increasing prevalence of neutropenia.

In the coming years, robust expansion is predicted in the febrile neutropenia market. The market is forecasted to enhance to $14.48 billion by 2029, with a compound annual growth rate (CAGR) of 6.4%. The expected growth in this timeframe is due to an increased use of immunosuppressive drugs, more research and development, favorable payback policies, additional investments, and a surge in leukemia instances. Key trends during this period would include quick molecular diagnostics, the implementation of antimicrobial stewardship & de-escalation therapy, immunotherapy & targeted treatments, risk stratification models, and progression in fungal biomarkers.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21187

What Are the Major Segments in the Febrile Neutropenia Market?
The febrile neutropenia market covered in this report is segmented -

1) By Treatment: Empirical Antibiotic Therapy, Targeted Antibiotic Therapy, Supportive Care
2) By Risk Factors: Chemotherapy-Induced Neutropenia, Transplant-Related Neutropenia, Genetic Disorders
3) By Etiology: Gram-Negative Bacteria, Gram-Positive Bacteria, Fungal Infections, Viral Infections
4) By Diagnostic Methods: Blood Cultures, Imaging Tests, Bone Marrow Aspiration

Subsegments:
1) By Empirical Antibiotic Therapy: Broad-Spectrum Beta-Lactams, Glycopeptides, Carbapenems
2) By Targeted Antibiotic Therapy: Antifungal Therapy, Antiviral Therapy, Gram-Positive Bacterial Therapy, Gram-Negative Bacterial Therapy
3) By Supportive Care: Granulocyte Colony-Stimulating Factors (G-CSFs), Intravenous Fluids, Antipyretics And Pain Management

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21187&type=smp

What Are The Driving Febrile Neutropenia Market Evolution?
The surge in cancer cases is projected to drive the expansion of the febrile neutropenia market in the future. Cancer involves a diverse array of diseases characterized by the unregulated multiplication of abnormal cells which have the potential to invade nearby tissues and metastasize to different body parts. An assortment of factors such as aging population, environmental & job exposure, genetic likelihood, and hormonal & reproductive variables contribute to the escalating incidence of cancer. Febrile neutropenia aids cancer patients by identifying an increased susceptibility to infections during chemotherapy, enabling early intervention and specific treatments to prevent grave complications. This in turn enhances patient outcomes and facilitates the continuation of cancer treatment on schedule. As per the American Cancer Society, a not-for-profit entity focused on cancer awareness located in the U.S., in January 2022, around 1.9 million new cancer instances and 609,360 cancer-induced deaths are anticipated, resulting in nearly 1,670 deaths each day in the country. Consequently, the rising prevalence of cancer is fueling the advancement of the febrile neutropenia market.

Which Firms Dominate The Febrile Neutropenia Market Segments?
Major companies operating in the febrile neutropenia market are Pfizer Inc., Sanofi S.A., Amgen Inc., Teva Pharmaceutical Industries Ltd., Sandoz, Fresenius Kabi, Aurobindo Pharma Ltd., Lupin Limited, Mundipharma GmbH, BeyondSpring Inc., Hospira Inc., Biocon Biologics Limited, Kyowa Kirin Co. Ltd., Coherus BioSciences Inc., Assertio Holdings Inc., Napp Pharmaceuticals Limited, Gennova Biopharmaceuticals Limited, Acrotech Biopharma Inc., Taiho Pharmaceutical Co. Ltd., Evive Biotech

What Trends Are Expected to Dominate the Febrile Neutropenia Market in the Next 5 Years?
The predominant companies in the febrile neutropenia market are aiming to develop cutting-edge biosimilar drugs to improve treatment availability. These biosimilar drugs have a structure, function, and effectiveness that closely mirror those of approved reference drugs, providing more affordable alternatives to the original biologics and enhancing patient accessibility while adhering to stringent regulatory norms. For instance, Fresenius Kabi, a German pharmaceutical company, obtained approval from the U.S. Food and Drug Administration (FDA) in September 2022 for its biosimilar Stimufend (pegfilgrastim-fpgk). This permission grants the use of Stimufend for patients with non-myeloid malignancies undergoing myelosuppressive chemotherapy, which can result in febrile neutropenia, a critical illness marked by reduced white blood cell count and fever. Fresenius Kabi aims to release Stimufend in a prefilled syringe form in early 2023 and also has plans to develop an on-body injector in the future.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/febrile-neutropenia-global-market-report

Which Is The Largest Region In The Febrile Neutropenia Market?
North America was the largest region in the febrile neutropenia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the febrile neutropenia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Febrile Neutropenia Market?
2. What is the CAGR expected in the Febrile Neutropenia Market?
3. What Are the Key Innovations Transforming the Febrile Neutropenia Industry?
4. Which Region Is Leading the Febrile Neutropenia Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.